Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

iBio now offers Fc fusion protein production services
April 2018
SHARING OPTIONS:

NEW YORK—iBio has expanded its CDMO capabilities and services to include the development and cGMP manufacturing of Fc fusion proteins for therapeutic pharmaceutical applications. The company reports that its proprietary technologies and facilities offer the ability to rapidly evaluate multiple lead candidates in early development stages, as well as significant cost and time savings during each stage of production scale-up. While Fc fusion proteins are traditionally developed using Chinese hamster ovary cells as a base, iBio states that using its plant-based technology instead “generates monoclonal antibody vectors entirely free of any viral transforming functions or contamination from parental lines.”
 
“We have proven Fc fusion manufacturing success with our own proprietary Fc fusion protein candidate for the treatment of fibrotic disease and with other Fc fusions, and now look forward to assisting others with promising Fc fusion proteins in preclinical and early clinical development,” said Dr. Barry Holtz, president of iBio CDMO.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.